Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOWER: Blinatumomab vs SOC in R/R B-precursor ALL
NCT02013167Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Jan 2014; status: terminated.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02013167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013167.